Inactive Instrument

Ablynx Share Price CBOE EUROPE EQUITIES

Equities

End-of-day quote CBOE EUROPE EQUITIES Other stock markets
- ^EUR	-

2018	AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	RE
2018	Sanofi : sees new acquisitions and drugs reviving growth	RE

AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	15/18/15	RE
Sanofi : sees new acquisitions and drugs reviving growth	27/18/27	RE
Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	17/18/17	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/18/29	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/18/29	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	29/18/29	RE
Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	22/18/22	RE
Ablynx : Sanofi's return to profit growth this year slower than hoped	07/18/07	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	30/18/30	RE
Ablynx : Chipmakers, Sanofi deal dominate European share trading	29/18/29	RE
Ablynx : Novo Nordisk remains on hunt for biopharma deals	29/18/29	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	22/18/22	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/18/22	RE
Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	22/18/22	RE
Associated British Foods : European shares edge higher as cyclicals back in favour	18/18/18	RE

Associated British Foods : European shares edge higher as cyclicals back in favour	18/18/18	RE
Ablynx : Bond sell-off hits European shares but boost banks	10/18/10	RE

Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	19/20/19	AQ
Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	19/18/19	GL
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	28/18/28	GL
Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	28/18/28	GL
Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	25/18/25	GL

SANOFI : a finalisé l'acquisition d'Ablynx	19/18/19
Les marchés européens marquent une pause, scrutent la politique italienne	14/18/14
Sanofi : A suivre aujourd'hui	14/18/14
SANOFI : détient 95,60% des actions d'ABLYNX	14/18/14
Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril	29/18/29

Managers	Title	Age	Since
Petrus Houwen CEO	Chief Executive Officer	-	01/19/01

Members of the board	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	01/19/01
Pieter Oldenziel BRD	Director/Board Member	-	01/19/01

Sector

	1st Jan change	Capi.
MODERNA, INC.	+28.28%	42.68B
IQVIA HOLDINGS INC.	-2.94%	42.4B
LONZA GROUP AG	+45.32%	40.04B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+7.37%	24.94B
ALNYLAM PHARMACEUTICALS, INC.	-20.82%	18.96B
MEDPACE HOLDINGS, INC.	+28.72%	12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.37%	11.95B
BIO-TECHNE CORPORATION	-1.19%	11.55B